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Background: 10-40% of patients with acute ischemic stroke (AIS) suffer an early neurological deterioration (END),
which may influence their long term prognosis. Multiple definitions of END exist, even in recently published papers.
In the search for causes, various biochemical, clinical, and imaging markers have been found to be associated to
END after AIS in some but not in other studies.
The primary aim of this study is to assess the contribution of END to functional level at 3 months post stroke
measured by modified Rankin Scale (mRS). Secondary aims are to identify factors and mechanisms associated with
END and to define the prevalence, degree and timing of END in relation to stroke onset, and to compare
Scandinavian Stroke Scale (SSS) and National Institute of Health Stroke Scale (NIHSS) based END-definitions.
We hypothesized that END detected by changes in NIHSS and SSS (according to previously published criteria) at a
threshold of 2 points indicate worsened prognosis, and that SSS is not inferior to NIHSS in predicting such a
change. We further hypothesized that clinical deterioration has several causes, including impaired physiological
homeostasis, vascular pathology, local effects and reactions secondary to the ischemic lesion, along with
biochemical disturbances.
Methods: Single-centre prospective observational study.
Participants: Previously at home-dwelling patients admitted to our stroke unit within 24 hours after ictus of AIS are
included into the study, and followed for 3 months. They are managed according to current procedures and
national guidelines. A total of 368 patients are included by the end of the enrolment period (December 31st 2013),
and the material will be opened for analysis by June 30th 2014.
Frequent neurological assessments, continuous monitoring, and repeated imaging and blood samples are
performed in all patients in order to test the hypotheses.
Discussion: Strengths and weaknesses of our approach, along with reasons for the methods chosen in this study
are discussed.
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Almost 60 years ago, a clinical course of stroke with in-
creasing severity of stroke symptoms after the onset was
described [1-3]. Terminology, scales used for clinical assess-
ment, time frames and threshold for clinical significance
have varied between studies on patients suffering what is
now most commonly termed early neurological deterio-
ration (END) [4-9].
END after acute ischemic stroke (AIS) has been found
to be related to case fatality and reduced functional out-
come [7,8,10-12], and has been associated with various
findings, subsequently generating various hypotheses.
A relation to thrombus extension has been suggested. A
study conducted in 1983 compared conventional angio-
graphic findings on admission to control angiographs in
15 ischemic stroke patients with neurological deterior-
ation. The findings indicated increased thrombus exten-
sion in 8 patients and occlusion of a collateral vessel in 4
patients [13]. However, such findings have not been veri-
fied in more recent studies using computer tomography
(CT) or magnetic resonance imaging (MRI) [14].
The literature includes studies where a positive correl-
ation has been found between END and various factors,
including age, previous diagnosis of diabetes and coron-
ary heart disease, greater extent of hypodensity on initial
CT scan [8], presence of a hyperdense media sign [8], of
MCA flow velocity changes, poor cerebral hemodynamic
reserve [15,16], increased stroke severity [17,18], presence
of an internal carotid artery (ICA) or middle cerebral
artery (MCA) occlusion [11], degree of carotid stenosis
[18], and with levels of plasma glucose [19-21], ferritin
[19], excitotoxic aminoacids in CSF and blood [22], pro-
inflammatory cytokines [21], nitric oxide in CSF [23], and
D-dimer [24] and with blood pressure values [7,18,25],
and body temperature [11].
Other studies have found a negative correlation between
END and blood pressure [6] and anti-inflammatory cyto-
kines [26].
High and low triglyceride values have been found to be
associated with haemorrhagic transformation, and low tri-
glyceride values have been found to be associated with an
increased risk of END [27].
Hypoxia is another suggested marker for END, which
may act both directly and via a steal phenomenon [28].
Stroke subtypes may have different risks of END. Lacu-
nar infarctions have been found to be associated with
END when compared to other ischemic stroke subtypes
with similar severity [29,30].
After thrombectomy and thrombolysis, other mecha-
nisms may additionally be at play. After initial recanaliza-
tion, reocclusion may occur and lead to END in some
patients [31], while new infarctions are found in areas
which are initially mildly hypoperfused in other patients.
Thus impaired clearance of emboli in hypoperfused tissuedistal to stenoses has been hypothesised [32,33]. Fur-
thermore, parenchymal haemorrhagic transformation may
cause END, and occurs more frequently in patients receiv-
ing recanalizing treatment [14]. A case of classical hyper-
perfusion syndrome after recanalization in a patient with
END has also been reported [34].
Various models have been used to describe mechanisms
leading to END, including collateral failure, clot progres-
sion, reocclusion (after initial reperfusion), recurrent stroke,
cerebral oedema, hemorrhagic transformation and seizures
[14], hemodynamic factors, excitotoxicity and inflammatory
mechanisms [35]. There is little evidence to support any
specific treatment which could reduce the impact of END
in patients suffering from such deterioration or protect
against END. However, stroke unit treatment is associated
with a reduced risk of END and recurrent stroke [36].
Whether it also reduces the impact of END on functional
level and mortality is not known. Thus, further research in
the area of END is needed.
Aims
Primary aim
To assess the relation between END after AIS and the
patient’s functional level at 3 months post stroke, includ-
ing case fatality.
Secondary aims
To define the prevalence, severity and timing of END
and early deteriorating episode (EDE) in relation to AIS
onset.
To identify factors and possible mechanisms associ-
ated with END and EDE after AIS.
To assess the relation between early deteriorating epi-
sode (EDE) and functional level at 3 months post stroke,
including case fatality.
To compare Scandinavian stroke scale (SSS)- and
NIHSS-based END-definitions.
To assess the impact on renal function and risk of
contrast induced nephropathy in stroke patients exam-
ined with intravenous contrast agents.
Methods
Definitions
Early neurological deterioration was defined in the
European progressing stroke study (EPSS) definition as
any significant neurological deterioration from baseline
to 72 hours [10]:
A significant neurological deterioration was primarily
defined as a decrease in the SSS items score for conscious-
ness, speech, gaze, arm, or leg by at least 2 points. Con-
sciousness was given precedence over the other signs [10].
An alternative definition of significant neurological
change was an increase in the total NIHSS score by at
least 2 points.
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and 72 hours as a neurological progression, and signifi-
cant deterioration or death within 72 hours as a progres-
sing stroke.
Early deteriorating episode (EDE) was defined as a sig-
nificant neurological worsening between two consecutive
assessments during the first 72 hours [10].
In this study, our definition of END is similar to that
of stroke progression used by EPSS, and EDE is defined
as a significant change between two consecutive assess-
ments, in accordance with the EPSS.
New stroke was defined as a new onset of focal or neuro-
logic deficits that could not be attributed to the presenting
lesion and were consistent with World Health Organization
definitions of stroke [37].
Contrast induced nephropathy (CIN) was defined as
an increase from the baseline serum creatinine concen-
tration of at least 44 μmol/L (0.5 mg/dL) or ≥25% within
48 to 72 hours after exposure to contrast media [38].Project context
This study is conducted within the stroke unit at St. Olav’s
Hospital, the University Hospital in Trondheim, Central
Norway. For stroke treatment it has a recruitment area of
230 000 inhabitants as a local hospital, serves another 100
000 for thrombolytic evaluation and -treatment, and serves
a total of 700 000 inhabitants in Mid-Norway for invasive
treatment, including thrombectomy. The comprehensive
stroke unit has a long tradition for combined acute treat-
ment and early mobilization [39], and offers an early sup-
ported discharge service [40]. It is organized as a unit
within the Department of Internal Medicine. All patients
above 60 years of age with acute stroke symptoms are ad-
mitted to this stroke unit, as long as there is treatment cap-
acity within the unit, while younger patients routinely are
admitted to the Department of Neurology.
On average, 325 patients per year have been discharged
from the stroke unit with a diagnosis of ischemic stroke
during the period. This number also includes patients
transferred from other departments after procedural
strokes, or after initial treatment in other wards in the
hospital.
All patients within the study receive medical treatment
and follow up according to current national guidelines and
local protocol. Both emphasise the importance of evaluat-
ing the patient’s physiological homeostasis and recommend
measures to restore it. In case of increasing symptoms, the
local protocol recommends an infusion of ½-1L Ringer-
acetate within 1–3 hours, while platelet inhibition with
both Aspirin and Clopidogrel may be considered after ex-
clusion of a haemorrhage.
Inclusion into this study should not affect length of
stay or treatment decisions.Study design
The present study is a prospective observational study,
performed in a single stroke unit from May 17th 2010 to
December 31st 2013, comparing patients with early neuro-
logical deterioration to those with no such deterioration.
Study population
This study intended to include consecutive patients admit-
ted to the stroke unit with acute stroke symptoms after ex-
clusion of haemorrhage on initial native CT examination.
The pilot study included independent patients <85 years
of age, admitted within 8 hours after debut of stroke symp-
toms, without haemorrhage, stroke sequelae, previously
known terminal illness or other condition which might
confound follow-up, other final diagnosis than stroke, or
contraindications to intravenous contrast agents. In the
main study, patients admitted within 24 hours were in-
cluded. After October 16th 2010, patients were no longer
excluded due to dependency, age, or contraindications to i.
v. contrast agents.
Thus, after the last revision the study intended to in-
clude all patients who were
 Admitted to the stroke unit with acute stroke
symptoms
 Admitted to the stroke unit within 24 hours after
ictus, and are
 Previously living in their own home
The exclusion criteria were
 Previously known preexisting condition which could
confound follow-up
 Consent could not be achieved
 Haemorrhage on native CT examination
 If a diagnosis other than acute ischemic stroke
provided at least as good an explanation to the
patient’s symptoms.
 No capacity to follow the patient according to the
study protocol.
Primary outcome
The effect of END according to the EPSS definition on
level of function and case fatality at 12 weeks, measured
by the modified Rankin Scale (mRS) compared to patients
without END.
Secondary outcomes
The effect on level of function and case fatality at 12 weeks,
measured by mRS, of EDE compared to the patients with a
stabile or improving course.
Prevalence, timing and severity of END and EDE ac-
cording to both SSS and NIHSS based definitions.
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ical, metabolic and vascular factors associated with END.
Initial CT and subsequent CT/MR images will be exam-
ined in order to identify a relation between END and find-
ings on imaging, and both ASPECTS and Pc-ASPECTS
scores will be used to quantify relevant findings.
The effect of END on level of function and case fatality
measured by mRS for patients fulfilling the criteria of
NIHSS based definitions of END.
An estimate for the minimal detectable change will be
calculated for both the NIHSS and SSS, based upon pre-
viously published data and the standard deviation found
in our study.
The effect in stroke patients of exposure to intravenous




Age, gender, level of function, medical history, and
current medical treatment at admission are collected on
admission and supplemented from relevant sources
while the patients are hospitalized. Medical treatment at
24 hours and 7 days (or discharge, whichever is sooner)
is also recorded.
Neurological assessments
Severity of stroke is assessed according to NIHSS, SSS
and a locally adapted abbreviated SSS form, including
the items for consciousness, speech, eye, arm, hand and
leg motor score (Similar to the standardised nursing
observations for stroke (SNOBS), only extended with the
hand item), with simultaneous blood pressure and oxy-
gen saturation measurements. Examinations according
to this latter form are performed at admission and every
6th hour until 48 hours, and at 60 and 72 hours. Add-
itionally, the full SSS and NIHSS are scored at admis-
sion, after 24, 48 and 72 hours, at 7 days (or discharge, if
after 72 hours and before 7 days), and 1 and 3 months.
All relevant personnel responsible to perform these
scores were trained in scoring according to these scales
prior to the study.
A subtype classification of stroke is performed accord-
ing to the Oxfordshire stroke project classification. The
information is based on the information available from
the score sheets, supplementary neurological examination
and relevant clinical information.
Functional level assessments
A pre-stroke mRS is estimated from available information,
and mRS is also scored at 24, 48 and 72 hours, at 7 days
and 1 and 3 months. Barthel ADL index is scored at 24
hours, 7 days, 1 and 3 months.Monitoring of homeostasis
A clinical status is performed at admission. Oxygen satur-
ation, ECG, and heart rate is monitored continuously for
the first 24 hours. The blood pressure is also measured
hourly for the same period. Except ECG, these data are
also registered at the SNOBS scorings during the first 24
hours, and blood pressure is registered at every SNOBS
scoring the first 72 hours.
Temperature and glucose are measured every 6th hour
the first 48 hours, and at 60 and 72 hours.
Blood samples
During the first 72 hours, routine blood tests are taken
repeatedly (Table 1).
Imaging
A native CT examination of the brain is performed at ad-
mission in order to exclude haemorrhage. A control exam-
ination is performed (either CT or MRI) at 24–72 hours in
order to visualize the extent of ischemic damage.
When clinically relevant (e.g. patients eligible for iv.
Thrombolysis or i.a. thrombectomy or suspected ca-
rotid stenosis) and not contraindicated, a brain and neck
contrast-enhanced CT-angiography is performed on one
of these occasions. Otherwise, carotid ultrasonography is
performed.
Complications
Medical complications are noted if reported in the med-
ical records.
Flowchart
Table 2 shows a flow chart of the examinations obtained
and when.
Supplementation of data
Missing data will be retrieved or estimated from medical
records or, for the neurological scorings, from other scor-
ing sheets. Scorings may also be adjusted when there is an
obvious inconsistency between the scoring and other clin-
ical information. In cases where data are missing and can-
not otherwise be reliably estimated in a clinical (functional
or neurological) score sheet, no change is assumed to have
occurred, and the former value is continued. Thus, pa-
tients who are discharged before 72 hours will be scored
in accordance to their last assessment, unless the medical
records report worsening within 72 hours.
Power and sample size estimations
Our stroke registry data indicate that approximately 500
patients are treated for ischemic stroke and intracerebral
haemorrhage combined at our hospital per year. Approxi-
mately 10% of all acute stroke admissions are caused by
haemorrhagic stroke. 70% of acute stroke patients are









Sodium X X X X
Potassium X X X X
Creatinine X X X X
Urate X
Osmolality X X X X
Haemoglobin X X X X
Leucocyte
count




Fibrinogen X X X
D-dimer X X X













CRP X X X X X
HS-CRP X X X
Lp(a) X
Albumin X
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on complications performed in our stroke unit, included
443 patients with ischemic stroke and 46 patients with
haemorrhagic stroke in 16 months, yielding an average of
332 patients per 12 months. Thus, at least 300 patients
were expected to be eligible for inclusion to the study per
year.
From previous studies, one in six patients was expected
to suffer a clinical deterioration according to current defi-
nitions. 80% power to detect a 15% increase in depend-
ence at a significance level of 0.05 needed 600 patients.
Due to the considerations above, the study was planned
for inclusion of 600 patients over the course of 2 years.Statistics
Relevant statistics will be used for descriptive data for the
population, and single- and multivariable analyses will be
applied in order to find factors related to END within our
material.An ordinal logistic regression analysis will be per-
formed in order to assess the effect of END on function
on the full range of the mRS.
Minimal detectable change will be estimated for both
END definitions, based on previously published data and
the standard deviation within this material.
Time plan of the study
A pilot study was performed in 2009. Inclusion in the
main study was initiated on May 17th 2010, and the last
patient was included in December 2013. A total of 401 pa-
tients have been included into the main study, of which 39
patients are excluded. The material from another 6 pa-
tients from the pilot study was sufficiently complete to be
included into this study, leaving a material of 368 patients
eligible for analysis in this study. Follow up for the last pa-
tient was complete April 7th 2014, and the complete data
set is not open for analyses until June 30th 2014.
Consent and inclusion into the study
All patients are asked to participate on arrival and receive
written information about the study and possible conse-
quences of participation. A written consent, or witnessed
informed oral consent, is obtained as soon as possible
after arrival. In cases when the patients are suspected not
to be able to give an informed consent, a proxy, typically
the next of kin is used, and delayed informed consent or
non-consent will be achieved from the patient in cases
when the patient is able to make such a decision at a later
time-point.
Ethics
The study and its pilot were approved by the Regional
Committee of Ethics in Medical Research (Central Norway)
(REK4.2010.492 and REK4.2008.2278).
Although monitoring itself is not harmful, the patients
may not be mobilized as early and to the extent they would
outside of this study. A limitation of early mobilization may
be harmful, although this has not been proven [41]. An in-
formed consent was obtained from all participants accord-
ing to the procedures reported above.
Discussion
This study aims to assess both the relation between END
according to different stroke scales and case fatality and
level of function after 3 months, and give a broad account
of association between END and potential associated
markers in a large material of unselected patients.
The primary aim in this study was to assess the relation
between END after AIS and the patient’s functional level at
3 months post stroke, including case fatality. This relation
has been found in previous studies, with various definitions
of END [7,8,10-12]. A study of the relation between END
and functional level and case fatality may still be relevant.
Table 2 Examinations and follow up in the Trondheim END Study
Inclusion 24 h 48 h 72 h 1 w 4 w 12 w
Consent +
Blood samples + + + +
Monitoring (24h; BP, ECG, O2,respiration) + +
Glucose X4 X4 X2 X1
Temperature X4 X4 X2 X1
ECG + + + +
SSS + + + + + + +
NIHSS + + + + + + +
CT + + or +
CT-angiography (+) (+) (+)
MRI (+) (+) (+)
Carotid ultrasound (+) (+)
Modified Rankin Scale Prestroke + + + + +
SNOBS + + + +
+denotes when examinations etc. should be performed Xn denotes that it should be performed n times, (+) denotes that an examination should be performed,
unless another optional examination is performed with success.
Helleberg et al. BMC Neurology 2014, 14:201 Page 6 of 9
http://www.biomedcentral.com/1471-2377/14/201Our comprehensive stroke unit is research driven, with
thorough documentation on its benefits, sustained up to
10 years after stroke, in regard to functional outcome and
survival compared to control [39,42,43], and also improved
functional outcome when combined with early supported
discharge [40,44]. Some of the benefit of the stroke unit
treatment may be due to a reduction of complications, in-
cluding stroke progression and recurrent stroke, which
may be due to comprehensive implementation of various
measures to secure physiological homeostasis [36]. Data
from our stroke unit on complications during 2002–2003
in unselected stroke patients found END in 18.9% of the
patients, which is rather low in a patient material with in-
tracerebral haemorrhage and AIS combined [37]. Thus,
there are reasons to believe that the incidence of END as
well as the effect of END on functional outcome and mor-
tality may have been reduced due to improvements in
treatment.
This study is based upon our day-to-day-treatment and
follow-up in the stroke unit. Thus, any relevant findings
from this study may be clinically applicable. Further, un-
like most studies in this area, this study applies repeated
neurological scorings, ideally every 6th hour the first 48
hours, and every 12th until 72 hours, which may allow
measures to be taken sufficiently early for these to be effi-
cient. This study may also quantify at which level deterior-
ation can reliably be detected, without causing the
excessive work-up expected by others [4].
Some of the choices made in the design and conduction
of the study constitute limitations, and the choices may
need to be justified.Mechanisms that have been used to explain END include
collateral failure, clot progression, reocclusion (after initial
reperfusion), recurrent stroke, cerebral oedema, haemor-
rhagic transformation and seizures [14], hemodynamic fac-
tors, excitotoxicity and inflammatory mechanisms [35].
These mechanisms may not exclude each other, but could
be seen as supplementary, and may be in play in various
degrees in different patients. The penumbra may increase
in response to systemic hypotension, intracranial hyperten-
sion, vasogenic oedema or hyperglycemia [45], hypoxia or
hypercapnia [28] and (re-)occlusion. The positive correl-
ation between risk of END and degree of carotid sten-
osis [18] may be seen as a marker for susceptibility for
hypotension, and thus END, as also reduced cerebral
hemodynamic reserve [15]. Hyper- and hypoglycaemia
[46] and fever [47] affect the metabolism in the tissue in a
way that may threaten the hypoperfused tissue. However,
not all mechanisms proven to be relevant after a stroke
are limited to the penumbra [33]. We have established an
examination programme in order to find factors and
mechanisms related to END, with special emphasis on
physiological homeostasis and hemodynamic factors. Fur-
ther, seizures are noted when observed in clinical practice,
new stroke may be detected by clinical observation or im-
aging, and cerebral oedema and haemorrhagic transform-
ation should be detected by imaging. Some blood tests
and CSF tests which have been associated with END have
been left out of the program due to cost and infeasibility.
Thus the exitotoxicity factors and some of the immuno-
logical factors cannot be explored within our study. How-
ever, in addition to markers present on admission, we
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risk factors for deterioration to a greater extent than previ-
ous studies, as our scorings give an opportunity to identify
when changes in neurological function occur, and the large
battery of tests within our protocol may help identify
causes for the deteriorations that occur.
The choice of definition of END, in studies as well as in
repeated clinical evaluation, deserves a thorough discussion.
In dealing with END definitions, as in other approaches to
define meaningful clinical change, both an anchor-based
approach and a distribution based approach should be ap-
plied [48]. Obviously, the first concern is that the change
found is clinically important (minimal important change).
One acceptable approach is anchoring the definitions in
endpoints, which has been done with various SSS-based,
NIHSS-based and CNS-based definitions, which have been
found to be related to a poor outcome [7,8,10-12].
In the EPSS validation, the relation between functional
level and inclusion or exclusion of different items, and also
the CNS definition, was found to be in favour of the EPSS
definition, and was again validated when tested against
two other definitions [10,12]. To our knowledge, no such
comparison exists between the NIHSS and the SSS.
As the EPSS definition was established when the study
was planned, and there was no agreement on NIHSS
definition [4,11,35], this study was planned with the
EPSS definition as main definition of END, which is well
anchored in clinical endpoints.
Although the distribution based approach to clinical im-
portant change has been much neglected within this area,
it has its strengths in taking the error of the measure-
ments in account, which is well expressed in the concept
of minimal detectable change (MDC) [48]. This may be
calculated from previously published data, supplemented
with our data in the case of SSS, but in the case of the
EPSS definition, an MDC for the full scale or relevant
items may have limited value.
Initially, the study protocol included a contrast en-
hanced CT-angiographic examinations of all patients on
admission and repeated at a routine control examination
after 36–72 hours, in addition to be repeated in case of
progression, in order to detect a possible association be-
tween thrombus progression and END. Introduction of
perfusion examination at some or all these examinations
was suggested. All such contrast-enhanced examinations
may lead to increased risk of contrast induced nephrop-
athy (CIN), in addition to risk associated with increased
radiation. The most commonly used definition of CIN is
an increase from the baseline serum creatinine concen-
tration of at least 0.5 mg/dL or at least 25% within 48 to
72 hours after exposure to contrast media, and has been
reported in 2% of patients in general population, increas-
ing to as much as 50% of patients with multiple risk fac-
tors, and depends on the volume of contrast given [38].Patients with previously known creatinine > 130 μmol/L
(>1,5 mg/dL), age >85 years of age, or known adverse reac-
tions to contrast agents would not be examined routinely
with CT-angiography (and subsequently CT-perfusion if
admitted within 8 hours), as the risk was considered
greater than a possible benefit. Thus, they initially were not
included into the study. After an early revision, these pa-
tients were examined with carotid ultrasound. After a
change in the clinical protocol, only patients eligible for
thrombectomy would be examined with a CT-angiography
for an acute assessment, and other patients only on clinical
indication. CT-perfusion was abandoned due to time loss.
This fact does not change the fact that patients have been
exposed to risk of CIN. This may be justified by findings
relevant for clinical treatment. As creatinine has been re-
peatedly taken, this allows an estimation of this risk in pa-
tients selected according to these criteria, and thus, an
estimation of the risk of CIN in patients exposed, can be
quantified.
Despite changes in inclusion criteria, far less than the
expected 300 patients per year were included. Due to
limited capacity in the stroke unit, some patients were
not primarily admitted, and were thus not eligible for
the study. Of the patients admitted to the stroke unit, an
important proportion was not included into the study.
Possible causes may be uncertainty about the diagnosis,
and that medical treatment and care had to be given pri-
ority over inclusion in this study. Selection bias can be
suspected. Patients receiving thrombolytic therapy are
always admitted to the stroke unit, and are followed ac-
cording to the study protocol, and may thus be more
prone to be included into the study. Patients with more
subtle stroke symptoms may less likely be included, as
mild stroke symptoms may be overlooked and symptoms
from posterior circulation may be less specific for stroke,
and thus believed to not be caused by other. These changes
may give inadequate estimates of incidence of the stroke
types and severity of stroke, and thus may give inadequate
estimates for incidence of progression and prognosis after
stroke. As some information concerning stroke severity ex-
ists in our stroke registry, the effect of a possible selection
bias may be discussed.
Despite these limitations, we believe that this study will
contribute to knowledge within this area.Abbreviations
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